started · updated
Boryung and Celltrion Pharm partner for diabetes drug sales
Boryung and Celltrion Pharm have signed a co-promotion agreement to jointly manage the domestic sales and marketing of the Nesina and Actos diabetes medication portfolio. Starting in January next year, the partnership will cover six types of oral treatments for type 2 diabetes, including Nesina (alogliptin), Actos (pioglitazone), and various combination therapies.
The Nesina and Actos product lines, which Celltrion acquired from Takeda in 2020, recorded 51.7 billion KRW in prescriptions last year according to UBIST. The collaboration aims to leverage the marketing expertise of both companies to strengthen the market position of these original drugs.
This agreement also supports the upcoming launch of Boryung Pharma Solution, a specialized sales and marketing subsidiary set to debut in January. By adding these DPP-4 inhibitor and TZD class drugs to its existing portfolio, which includes products like Trubuddy and Trudapa, Boryung intends to offer a wider range of treatment options for patients.
Entities
Actos · Boryung · Boryung Pharma Solution · Celltrion Pharm · Nesina · Takeda